# A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

> **NCT01830855** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 3596 (actual)

## Conditions studied

- Meningococcal Vaccine

## Interventions

- **BIOLOGICAL:** rLP2086
- **BIOLOGICAL:** rLP2086
- **BIOLOGICAL:** rLP2086
- **BIOLOGICAL:** Havrix (HAV)
- **BIOLOGICAL:** Saline

## Key facts

- **NCT ID:** NCT01830855
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 3596 (ACTUAL)
- **Last updated:** 2016-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01830855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01830855, "A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01830855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*